|Day Low/High||14.63 / 15.01|
|52 Wk Low/High||5.61 / 25.10|
Cronos will acquire an 84,000-square-foot fermentation and manufacturing facility.
Analysts say nation will turn a new leaf, changing federal law within a few years, as cannabis industry expected to grow big time over next decade.
It all comes down to matching my time frame.
Aurora Cannabis is currently the portfolio's second best performer.
Here's how to play OGI stock right now.
What are we too bullish about, asks Jim Cramer? Depending on the sector, investors have good reason to be optimistic.
Jim Cramer takes a look at PepsiCo, Blackstone, Grocery Outlet Holding Corp. Mastec, International Paper, Arrowhead Pharma, Organigram Holdings and more.
Is prohibition the real factor propping up projections for demand and pricing in the cannabis market?
Canopy Growth stock is taking a beating on Friday after the company disappointed investors with its quarterly results. Here's the must-hold support level for the stock now.
Canopy's earnings losses could just be a stepping stone to becoming the industry leader.
An investing app indicates Aurora Cannabis is popular with young investors, while we also intend to monitor alternative energy firm Plug Power.
Tilray is erupting higher and breaking over downtrend resistance. It's been a long time coming for this troubled cannabis stock.
Bank of America lifts its price target on Cronos to $20 from $13.
The FDA will discuss the safety and product quality of CBD-derived compounds in a public hearing Friday.
The company's announcement comes ahead of an FDA's public hearing on the legalization of CBD-infused foods and beverages on Friday.
Jim Cramer reviews stocks poised to profit, and those at risk -- until we get some sign of a truce in the trade war.
Energy Recovery has stabilized above our target, warranting some action. Plus, Aurora Cannabis reports earnings.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CRON, SFS, TCS, TDW, TPRE Downgrades: AMBC, CARG, IRM, MUR, PEGI, RDFN, RL, TBI Initiations: RDVT Read on to get TheStreet Quant Ratings' detailed report:
Cronos announces that it has entered into a multi-year private label cannabis concentrate supply agreement MediPharm Labs.
The markets staged a big reversal Friday after the China tariffs and Uber's IPO thud. Jim Cramer's got your game plan for next week.
Jim Cramer takes a look at ADT, Domo, Aurora Cannabis, Seaspan, Walgreens Boots Alliance, Sirius XM Radio and more.
Cronos shares are falling despite easily topping analysts' earnings estimates.
Should you buy cannabis ETF instead of attempting to pick an individual stock?
The tobacco maker misses expectations in the first quarter on both the top and bottom lines. It reiterates 2019 earnings guidance.
Pot stocks may have cooled off in recent months but the industry is still hot and Bank of America Merrill Lynch expects it to get hotter as it reaches maturity.
It's 420. TheStreet's Jim Cramer discusses Canopy Growth, Tilray, Constellation Brands and other investing opportunities in the cannabis sector!
CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.